SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: A comprehensive multidisciplinary team approach

R. A. Werner, Christina Bluemel, M. Lassmann, T. Kudlich, T. Higuchi, Egesta Lopci, M. Allen-Auerbach, Patrick M. Colletti, Domenico Rubello, M. C. Zatelli, Ken Herrmann

Research output: Contribution to journalArticle

Abstract

The overexpression of somatostatin receptors on the tumor cell surface of neuroendocrine tumors (NETs) detected by multimodal functional imaging modalities such as SPECTand PET tracers constitutes a therapeutic option using targeting radiolabeled compounds. We will introduce the theranostic concept in general, explain in more detail its development in NETs, and discuss available SPECT and PET tracers regarding their potential for diagnostic imaging, visualization of target expression, and treatment tailoring.Moreover,wewill discuss the currently available peptide receptor radionuclide therapy principles and compare them to previously published studies. Finally,wewill discusswhich newconcepts will most likely influence the theranostic treatment approach in NETs in the future.

Original languageEnglish
Pages (from-to)e271-e277
JournalClinical Nuclear Medicine
Volume40
Issue number5
DOIs
Publication statusPublished - May 22 2015

Keywords

  • neuroendocrine tumors
  • PET-based patient-tailored
  • SPECT-based patient-tailored
  • tailored treatment
  • team approach

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Fingerprint Dive into the research topics of 'SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: A comprehensive multidisciplinary team approach'. Together they form a unique fingerprint.

  • Cite this

    Werner, R. A., Bluemel, C., Lassmann, M., Kudlich, T., Higuchi, T., Lopci, E., Allen-Auerbach, M., Colletti, P. M., Rubello, D., Zatelli, M. C., & Herrmann, K. (2015). SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: A comprehensive multidisciplinary team approach. Clinical Nuclear Medicine, 40(5), e271-e277. https://doi.org/10.1097/RLU.0000000000000729